Elevated serum osteoprotegerin levels predict in-hospital major adverse cardiac events in patients with ST elevation myocardial infarction

Journal of Cardiology

Volumn 60, Issue 5, 2012, Pages 355-360

  Çanga, Aytun ^a   Durakoĝlugil, Murtaza Emre ^b   Erdoĝan, Turan ^b   Kirbaş, Aynur ^b   Yilmaz, Adnan ^b   Çiçek, Yüksel ^b   Ergül, Elif ^a   Çetin, Mustafa ^a   Kocaman, Sinan Altan ^a  

^a Rize Education and Research Hospital   (Turkey)

^b RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Major adverse cardiac events; Osteoprotegerin; Primary percutaneous coronary intervention; Reperfusion; ST elevation myocardial infarction

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; BALLOON; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; INOTROPISM; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOLYSIS IN MYOCARDIAL INFARCTION RISK SCORE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; FEMALE; FORECASTING; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES;

EID: 84868624711     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.05.010     Document Type: Article

References (31)

1. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329.
2. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010, 55:2049-2061.
3. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
4. LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75.
5. Xiang G.D., Xu L., Zhao L.S., Yue L., Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006, 55:2126-2131.
6. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., Jain T., Gruntmanis U., McGuire D.K., de Lemos J.A. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
7. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
8. Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180.
9. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
10. Hachinohe D., Jeong M.H., Saito S., Kim M.C., Cho K.H., Ahmed K., Hwang S.H., Lee M.G., Sim D.S., Park K.H., Kim J.H., Hong Y.J., Ahn Y., Kang J.C., Chae S.C., et al. Clinical impact of thrombus aspiration during primary percutaneous coronary intervention: Results from Korea Acute Myocardial Infarction Registry. J Cardiol 2012, 59:249-257.
11. Cho Y.W., Jang J.S., Jin H.Y., Seo J.S., Yang T.H., Kim D.K., Kim D.I., Lee S.H., Cho Y.K., Kim D.S. Relationship between symptom-onset-to-balloon time and long-term mortality in patients with acute myocardial infarction treated with drug-eluting stents. J Cardiol 2011, 58:143-150.
12. Crisafulli A., Micari A., Altavilla D., Saporito F., Sardella A., Passaniti M., Raffa S., D'Anneo G., Luca F., Mioni C., Arrigo F., Squadrito F. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005, 109:389-395.
13. Sandberg W.J., Yndestad A., Oie E., Smith C., Ueland T., Ovchinnikova O., Robertson A.K., Muller F., Semb A.G., Scholz H., Andreassen A.K., Gullestad L., Damas J.K., Froland S.S., Hansson G.K., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006, 26:857-863.
14. Omland T., Ueland T., Jansson A.M., Persson A., Karlsson T., Smith C., Herlitz J., Aukrust P., Hartford M., Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
15. Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Apple F.S., Galvani M., Katus H.A., Newby L.K., Ravkilde J., Chaitman B., Clemmensen P.M., Dellborg M., Hod H., Porela P., Underwood R., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
16. Killip T., Kimball J.T. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967, 20:457-464.
17. Morrow D.A., Antman E.M., Giugliano R.P., Cairns R., Charlesworth A., Murphy S.A., de Lemos J.A., McCabe C.H., Braunwald E. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001, 358:1571-1575.
18. Morrow D.A., Antman E.M., Charlesworth A., Cairns R., Murphy S.A., de Lemos J.A., Giugliano R.P., McCabe C.H., Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000, 102:2031-2037.
19. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
20. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985, 312:932-936.
21. Gibson C.M., Murphy S.A., Rizzo M.J., Ryan K.A., Marble S.J., McCabe C.H., Cannon C.P., Van de Werf F., Braunwald E. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. thrombolysis in myocardial infarction (TIMI) study group. Circulation 1999, 99:1945-1950.
22. Gibson C.M., Cannon C.P., Murphy S.A., Ryan K.A., Mesley R., Marble S.J., McCabe C.H., Van De Werf F., Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000, 101:125-130.
23. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., Squire I.B., Gullestad L., Bollerslev J., Dickstein K., Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
24. Andersen G.O., Knudsen E.C., Aukrust P., Yndestad A., Oie E., Muller C., Seljeflot I., Ueland T. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011, 97:460-465.
25. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., Ewings M.E., Mohaupt M., Herring S.W., Clark E.A. Osteoprotegerin a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001, 166:1482-1491.
26. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., Rong J., Corey D., Hoffmann U., Fox C.S., Vasan R.S., Benjamin E.J., O'Donnell C.J., Kathiresan S. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010, 30:1849-1854.
27. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001, 276:20659-20672.
28. Mangan S.H., Van Campenhout A., Rush C., Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 2007, 76:494-505.
29. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., Celeghini C., Capitani S., Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006, 169:2236-2244.
30. Secchiero P., Candido R., Corallini F., Zacchigna S., Toffoli B., Rimondi E., Fabris B., Giacca M., Zauli G. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006, 114:1522-1530.
31. Erkol A., Pala S., Kirma C., Oduncu V., Dundar C., Izgi A., Tigen K., Gibson C.M. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 2011, 107:857-862.